Blog

ValiRx plc (LSE:VAL) has reported its audited results for 2025, outlining the completion of a strategic review that has narrowed the company’s focus to three key priorities while repositioning its Inaphaea BioLabs division to primarily support internal development programmes alongside selected external partnerships. The company also benefited from non-dilutive R&D tax credits and continues to utilise its patient-derived cell (PDC) biobank and collaborative network to advance future pipeline opportunities.

Cost Reduction and Portfolio Rationalisation

During the year, ValiRx reduced administrative expenses by more than £300,000 through board and workforce restructuring measures. The company also exited several evaluation and licensing arrangements that were considered outside its strategic focus, while entering new evaluation agreements with organisations including Altus Healthcare and McGill University as part of a more selective commercial approach.

The group also terminated its TheoremRx agreement, established Blue Ribbon Bio to progress the VAL201 programme, and licensed VAL401 to Ambrose Healthcare in return for an equity interest. In addition, ValiRx expanded its capabilities in AI-driven biomarker discovery and in-silico clinical trials through partnerships with Cellomatics Biosciences and TwinEdge Bioscience.

Financial Performance and Going-Concern Considerations

ValiRx recorded a total comprehensive loss of £2.23 million for the year, reflecting substantial goodwill impairments related to VAL401 and VAL201. Excluding these non-cash charges, the company reported an improvement in its underlying loss position.

Cash resources declined to £0.79 million at the end of 2025, leading management to implement further measures after the reporting period to conserve capital. These actions included voluntary salary reductions and changes to the company’s advisory board structure. Auditors also identified a material uncertainty relating to going concern, citing the group’s dependence on future fundraising activity to support ongoing operations.

Strategic Outlook

Management believes the completion of its strategic and operational restructuring has left the business better positioned to navigate the challenging funding environment facing early-stage biotechnology companies. The company is now operating with a leaner cost base and a more selective framework for assessing new opportunities.

ValiRx intends to focus on advancing higher-quality later-stage assets, extracting greater value from the Inaphaea biobank platform, and expanding targeted academic and commercial collaborations. The company believes this approach could improve its ability to secure partnership agreements, attract non-dilutive funding and generate long-term value for shareholders.

From an investment perspective, ValiRx continues to face pressure from ongoing losses and its reliance on external financing. Technical indicators point to a generally bearish trend, although some scope for short-term upside remains. Valuation metrics are also challenged by a negative price-to-earnings ratio and the absence of a dividend yield.

More about ValiRx

ValiRx plc is a UK-based life sciences company focused on developing early-stage therapies in oncology and women’s health. The business uses its translational research expertise to advance novel drug candidates from pre-clinical development towards clinical readiness and commercial partnering opportunities.

Through its Inaphaea BioLabs division, which operates a patient-derived cell biobank, and a broad network of academic and industry collaborators, the company aims to reduce development risk and accelerate asset progression. ValiRx typically advances programmes to a value-inflection point before seeking outlicensing or further development through dedicated subsidiary structures and strategic partners.

GEO Exploration Limited (LSE:GEO) has reported positive initial field results from its Gorge Project in Western Australia, where visible and coarse gold has been observed in quartz vein samples at the Gorge Mine, 401 and Central Zone prospects. Geological mapping and structural measurements indicate favourable conditions for orogenic gold mineralisation, supported by extensive historic hard-rock workings and well-exposed metasedimentary rocks.

The company has collected 35 rock chip samples and 246 orientation soil samples across key target areas, with soils submitted for laboratory analysis to shape a broader geochemistry campaign. Identification of copper-rich gossan and evidence of historic production of lead and silver underscore the project’s multi-commodity potential, while confirmed access, water sources and historic drill collar locations strengthen the groundwork for future systematic follow-up work and potential drilling, subject to approvals.

More about GEO Exploration Limited

GEO Exploration Limited is a mineral exploration company listed on London’s AIM market, focused on gold and multi-commodity projects in Western Australia. The company targets orogenic gold systems and associated base metals such as copper, lead and silver, advancing early-stage assets through systematic fieldwork and geochemical programmes.

Proteome Sciences plc (LSE:PRM) has announced the award of a major new clinical contract tied to its target engagement and chemoproteomics platform, marking another milestone ahead of an anticipated clinical trial programme expected to begin later in 2026. The company said the agreement reflects growing traction for its chemoproteomics offering and follows strong industry engagement at the American Society for Mass Spectrometry conference in San Diego, highlighting increasing demand for its specialist proteomics expertise.

The contract is expected to strengthen Proteome Sciences’ revenue opportunities while expanding its involvement in clients’ clinical development activities. As programmes advance, the company could benefit from additional follow-on work, reinforcing its position within the contract proteomics sector. Greater exposure among drug development and mass spectrometry professionals may also support future growth in higher-value chemoproteomics projects.

Outlook and Key Considerations

Despite positive commercial momentum, Proteome Sciences continues to face financial challenges. The company has been impacted by lower revenues, negative gross margins, ongoing losses and a balance sheet under pressure from increasing debt levels and significantly negative equity.

From a market perspective, technical indicators provide only limited support. While the shares have experienced a short-term recovery, they remain below the 200-day moving average and the MACD indicator remains negative. Valuation metrics are also constrained by continuing losses, resulting in a negative price-to-earnings ratio, while dividend data remains unavailable.

More about Proteome Sciences

Proteome Sciences plc specialises in contract proteomics services designed to support drug discovery, clinical development and biomarker research. The company uses proprietary technologies to analyse tissues, cells and biological fluids, helping researchers identify disease biomarkers and better understand therapeutic targets.

Its technology portfolio includes SysQuant, TMT MS2 and chemoproteomics platforms such as Solvent Shift and TMTcalibrator, which provide high-sensitivity target identification, mechanism-of-action analysis and biomarker discovery across a broad range of plasma proteins.

The company also develops targeted mass spectrometry assays that deliver highly accurate biomarker measurements in situations where conventional immunoassays are not available. Through the combination of protein depletion techniques and extensive proteome coverage, Proteome Sciences aims to provide pharmaceutical and biotechnology companies with advanced analytical capabilities for clinical and translational research programmes.

Central Banks Shift Focus Back to Inflation

Barclays believes a growing number of major central banks are becoming more focused on controlling inflation, a development that could reduce one of the key drivers behind the strong performance of global equity markets in recent years.

The change comes after a series of policy decisions from leading central banks, many of which cited inflation risks linked to higher energy costs following the Iran conflict and disruptions to shipping through the Strait of Hormuz.

The European Central Bank delivered its first interest-rate increase since 2023, while the Bank of Japan raised borrowing costs to their highest level since 1995. Both institutions pointed to concerns that energy-related price pressures could spread across broader areas of the economy.

Federal Reserve Adopts a Firmer Tone

Although the Federal Reserve left interest rates unchanged this week, policymakers signalled a more hawkish stance than markets had expected.

Nine Fed officials now anticipate at least one additional rate increase before year-end, compared with none in the central bank’s March projections. Investors also focused on the wording of the Fed’s latest statement under Chair Kevin Warsh, which emphasised the goal of achieving “price stability” while omitting references to maximum employment.

The Bank of England also kept rates on hold, but Barclays noted that the voting split continued to reflect a hawkish bias despite softer inflation and labour market data.

Liquidity Could Become a Headwind for Stocks

Barclays strategist Emmanuel Cau and his team said recent developments represent “a clear shift in the global monetary policy backdrop.”

They argued: “After a prolonged period of synchronized rate cuts across the Western world, the tailwind from monetary policy easing is behind us. At the same time, uncertainty around the reaction function of central banks, particularly the balance between growth and inflation risks, may contribute to higher bond market volatility.”

The analysts cautioned that a more aggressive Federal Reserve could eventually begin to undermine one of the main supports for equity markets.

According to Barclays, if the Fed were to move “more decisively” toward fighting inflation and enter another tightening cycle, “it would start to squeeze liquidity and weaken a key pillar of support that has underpinned bullish equity market returns over the past two years.”

While the bank stressed that this is not its “base case,” it remains “a risk to monitor.”

U.S.-Iran Agreement Offers Some Relief

Despite concerns over monetary policy, Barclays highlighted the positive impact of the interim peace agreement between the United States and Iran.

The analysts described the deal as “a welcome relief” for investors, noting that lower geopolitical risks have contributed to falling oil prices and eased some inflation concerns.

Markets are now closely watching the reopening of the Strait of Hormuz, through which around one-fifth of global oil and liquefied natural gas shipments passed before the conflict. Although shipping activity has started to recover, some strategists believe it could take time before traffic returns to pre-war levels.

Europe May Be Positioned to Benefit

Barclays sees improving opportunities in Europe as macroeconomic conditions potentially strengthen during the second half of the year.

The analysts said: “From a regional perspective, the potentially better macro outlook for [the second half] should be supportive of [year-to-date] laggards such as Europe, leading us [to] close our underweight on the region, particularly with positioning still skewed toward a tech/semis-heavy United States.”

They also highlighted potential opportunities within consumer-focused sectors. “At the sector level, as lower oil prices boost consumer confidence from the lows, the risk-reward for some consumer cyclicals, most notably for luxury, should improve even after their recent short squeeze led bounce,” the Barclays analysts said.

JPMorgan believes the semiconductor sector is becoming increasingly vulnerable to bouts of sharp volatility as investor positioning reaches elevated levels and valuations continue to stretch.

In a research note on Thursday, analyst Nikolaos Panigirtzoglou warned that rising volatility combined with concentrated exposure is “raising the risk of more frequent semiconductor ‘VaR shocks’ from here,” pointing to the early-June selloff as an example of how quickly market conditions can deteriorate.

The bank identified concentration as one of the biggest risks facing the sector. As semiconductor stocks occupy a larger share of global equity indices, Panigirtzoglou said their weight “can become binding for funds with self-imposed risk limits,” potentially triggering forced reductions in exposure during periods of stress.

Valuation is another area of concern. JPMorgan noted that semiconductor companies now command a market-capitalization-to-revenue ratio within global indices that exceeds six times, a level significantly higher than that of the Magnificent Seven stocks in the S&P 500 when Broadcom is substituted for Tesla.

The bank also highlighted a potential catalyst for volatility in the near term. End-of-quarter and end-of-month portfolio adjustments could result in roughly $165 billion flowing out of equities and into bonds, creating additional pressure on sectors that have become heavily owned by investors.

Outside equities, JPMorgan pointed to growing risks in digital assets. The bank observed that bitcoin mining profitability has become increasingly dependent on cryptocurrency prices, suggesting that a larger share of miners are operating close to break-even levels.

JPMorgan concluded that while concentration has historically supported momentum during powerful rallies, the semiconductor sector’s current combination of rich valuations, crowded positioning and elevated volatility leaves it increasingly exposed to sharper market swings.

The International Energy Agency has downgraded its forecast for global oil demand in 2026, pointing to prolonged supply disruptions in the Gulf region, while expecting conditions to improve steadily over the following year.

The agency now forecasts a decline of 1.1 million barrels per day in global oil demand next year, compared with its previous estimate for a reduction of 420,000 barrels per day. Higher energy costs and ongoing supply constraints were cited as the primary drivers behind the revision.

Demand is expected to recover in 2027, with the IEA projecting growth of 2 million barrels per day as trade routes reopen, supply chains stabilize and economic activity strengthens.

Diplomatic Progress Offers Hope for Energy Markets

The agency highlighted the preliminary agreement reached between Washington and Tehran as a major development in efforts to resolve the conflict.

A formal signing is expected later this week, and the IEA described the agreement as the most significant diplomatic breakthrough since hostilities began.

“While details of the deal have yet to be clarified and several issues remain outstanding, it is an encouraging step forward,” the IEA said. “A full recovery will not be immediate, however, as mines will have to be removed from the main shipping lanes and supply chains will take time to normalise.”

Crude Prices Extend Weekly Losses

Oil prices continued to retreat as traders responded to improving geopolitical sentiment.

Brent crude slipped below $80 per barrel, while WTI traded around $76. Brent has now fallen more than 8% this week and is trading at levels not seen since early March.

The decline reflects growing expectations that global energy supplies will gradually recover if the agreement proceeds as planned.

Supply Recovery Expected Next Year

The IEA forecasts global oil supply will fall by 3.9 million barrels per day in 2026, largely because significant volumes remain stranded in the Persian Gulf.

Roughly one-fifth of the world’s oil supply continues to be affected by the disruption, although the agency expects a substantial rebound next year as exports and shipping activity resume.

Production in May remained 13.6 million barrels per day below pre-conflict levels, while exports from Gulf producers were down 1.1 million barrels per day and almost 15 million barrels per day below February levels.

Inventory Drawdowns Highlight Market Tightness

Global oil stockpiles continued to shrink during May, declining by 143 million barrels.

Since the conflict began, inventories have been falling at an average rate of 3.8 million barrels per day, underscoring the pressure on available supplies.

Meanwhile, OECD government inventories fell by 163 million barrels, reaching their lowest level in more than three decades.

Despite signs of diplomatic progress, the agency indicated that rebuilding supply chains and restoring market balance will remain a gradual process.

The dominance of artificial intelligence stocks in global equity markets is drawing comparisons with the late stages of the dot-com boom, although KB Securities believes the trend may indicate continued strength rather than an imminent reversal.

Analyst Euntaek Lee said in a research note that current market conditions are “largely the same” as those witnessed in 1999, when investors overwhelmingly favored internet-related companies and largely ignored sectors with strong underlying earnings performance.

Lee pointed out that healthcare and financial stocks enjoyed robust earnings-driven gains in 2025 but “have been left out of the rally simply because they are not AI plays.”

The analyst also highlighted similarities in investor sentiment. During the dot-com bubble, stocks frequently rallied on announcements linked to internet strategies, regardless of their earnings prospects.

According to Lee, today’s AI market is exhibiting comparable behavior, with shares “skyrocketing on news of a visit by Jensen Huang, or a hint of forays into AI/robotics, despite the absence of related earnings.”

Rather than viewing the narrowing leadership as a clear signal of market exhaustion, Lee argued that concentration can often accompany the strongest phases of a bull market.

“History shows that, in many cases, rising concentration indicates that the market still has momentum,” he wrote.

Even so, the analyst cautioned that excessive concentration can eventually create vulnerabilities. He noted that “rally broadening is not necessarily healthy” and “may be a sign that the rally is approaching its end.”

For now, KB Securities expects leadership within equity markets to become even more concentrated, following a pattern commonly observed during the final stages of previous speculative booms.

Investor sentiment is approaching some of the strongest levels seen in recent years, but Bank of America believes the current environment does not yet point to a significant top in global risk assets.

The bank’s June Global Fund Manager Survey showed its Bull & Bear Indicator rising to 8.9, a level that traditionally generates a technical sell signal. Nevertheless, strategist Michael Hartnett noted that cash holdings increased modestly during the month, suggesting investors have not become excessively positioned.

Based on historical patterns, Hartnett said “this is not a ‘big top’ for risk assets,” and argued that a more meaningful turning point “will be signaled by bonds & voters.”

Economic Confidence Continues to Build

Fund managers expressed greater confidence in both economic growth and corporate earnings prospects, with expectations reaching their highest levels in three months.

At the same time, concerns about higher interest rates are increasing. Expectations for tighter monetary policy are now at their highest point since late 2022, while 40% of survey participants expect the Federal Reserve to raise rates over the next year.

Most respondents also expect Fed Chair Kevin Warsh to deliver a “hawkish hold” when policymakers conclude their latest meeting.

Portfolio Allocations Become More Defensive

Despite the optimistic outlook, investors made several adjustments to reduce risk exposure.

Global equity allocations were trimmed, technology positions were reduced and European stocks experienced their largest underweight positioning since late 2024.

In contrast, fund managers increased exposure to Japanese equities, banks and materials producers, while gold moved into the fair-value category for the first time in more than a year.

Inflation and AI Speculation Remain Key Risks

The survey identified inflation as the primary concern facing markets.

A potential “second wave inflation” scenario ranked as the top risk, while fears of an “AI bubble” remained firmly in second place.

Meanwhile, long positions in semiconductor stocks continue to dominate investor portfolios, with 80% of respondents describing the trade as overcrowded — the highest reading ever recorded by the survey.

Contrarian Investors May Find Opportunities Elsewhere

While investor enthusiasm remains elevated, Bank of America believes several overlooked areas could offer attractive opportunities.

The firm highlighted long-dated bonds, European equities and consumer-focused stocks as the most appealing contrarian trades as investors move into the summer period.